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Dear Prof Marc Hochberg,
Article Type: Systematic Review with Meta-analysis
Submission of Manuscript: Secular changes in functional disability, pain, 
fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-
analysis.
Carpenter, L.1, Barnett, R.1, Mahendran, P.1, Nikiphorou, E.2, Gwinnutt, J.3, 
Verstappen, S.3, Scott, D.L.2 & Norton, S.1,2
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3Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal 
Research, Division of Musculoskeletal and Dermatological Sciences, School of 
Biological Sciences, Faculty of Biology, Medicine and Health, University of 
Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Thank you for considering the following manuscript for publication in Seminars in 
Arthritis and Rheumatism. The paper documents a systematic review of all early 
Rheumatoid Arthritis (RA) cohorts with longitudinal summary data on pain, 
fatigue or mental well-being, along with disease activity and functional disability.
The aim of the review was to investigate the long-term trajectory of patient 
reported outcomes (pain, fatigue and mental well-being) in patients diagnosed 
with early RA at different periods over the last 30-years and establish whether 
advances in the treatment of RA have led to improvements in these patient 
reported measures. This was achieved using longitudinal meta-analytic 
techniques rarely seen in the medical literature.
In total, 46 cohorts from 41 published studies were identified, contributing a total 
of 18,046 patients, with longitudinal data. Of those, 29 cohorts provided 
sufficient data on 10,132 patients on the outcomes of interest for meta-analysis.
The systematic review was conducted by LC, RB and PM, analysis and 
manuscript preparation were performed by LC and SN, and drafts of the 
manuscript where reviewed and modified by EN, JG, SV and DLS. Sam Norton is a 
Fellow of MQ: Transforming Mental Health and Arthritis Research UK (MQ16IP18). 
Lewis Carpenter time is fully supported by MQ16IP18. Prof David L Scott’s time is 
funded by a NIHR Programme grant (RP-PG-0610- 10066).
Sincerely,
Dr Lewis Carpenter
Comments from the editors and reviewers:
-Reviewer 1
The authors have endeavored to address the reviewers’ comments 
effectively.  At the same time, it remains the case that joint counts, which 
are components of DAS28, are more likely to improve with placebo than 
self-report measures (1)(one of the authors of that reference is an author 
of this manuscript), apparently on the basis of bias on the part of 
physicians and study coordinators.  
The disclaimer about different numbers of joints in different studies is 
somewhat legitimate, but could be addressed in part as percent of 
maximum for any joint count, although that approach may be limited by 
the fact that certain joints are more likely to be affected than others.  
Also, there appears a somewhat excessive emphasis on p values, 
reflected in a comment that a difference “did not reach statistical 
significance.”  Many clinically important differences may not have a P 
value <0.5, and many p values <0.5 are not clinically important.  The 
authors might review the manuscript to deemphasize p values, although 
they may choose to ignore this suggestion. 
 1.    Strand V, Cohen S, Crawford B, Smolen JS, Scott DL, Leflunomide 
Investigators G. Patient-reported outcomes better discriminate active 
treatment from placebo in randomized controlled trials in rheumatoid 
arthritis. Rheumatology (Oxford). 2004;43(5):640-7.
Response: We thank the reviewer for highlighting just how 
important this aspect of the manuscript is. We have to conduct 
the additional analysis using the data available to shed light on 
this issue in the review. It was not feasible to email all the 
authors to request the data where it was not reported in the 
manuscript, therefore a sensitivity analysis was conducted using 
the data that was readily reported on not only the joint counts, 
but also acute phase markers.
We have provided this additional analysis as part of the 
supplementary material and alluded to this analysis in the 
‘Sensitivity Analysis” section of the results: 
“Additional analysis investigated the progression of the sub-components of the DAS28; 
the Swollen Joint Count (SJC), Tender Joint Count (TJC), C-Reactive Protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR), in a sub-group of cohorts reporting this data. Of 
the 37 cohorts with DAS28 data, 25 had data on SJC, 23 on TJC, 22 on CRP and 18 on ESR. 
Whilst SJCs, TJCs and CRP showed greater declines in post-2002 compared to pre-2002 
cohorts, the estimates over the follow-up periods were inconclusive due to low levels of 
data over the follow-up. Details of this sub-analysis are presented in the supplementary 
material.”
Reviewer 2
  - The authors carried out an impressive study and were responsive to the 
reviewers' comments and suggestions. I have just one minor question 
about the longitudinal statistical analysis. In the longitudinal analysis, it 
appears that the authors performed a hierarchical meta-regression, to 
investigate heterogeneity while accounting for the fact that a study can 
contribute estimates at multiple time points. That is, a hierarchical version 
of this:
https://handbook-5-1.cochrane.org/chapter_9/9_6_4_meta_regression.htm
If that is accurate, then I recommend using the meta-regression language 
somewhere when describing the method.
Response: We thank the reviewers for the positive remarks on 
the paper and we are pleased that our responses were well 
received. We agree with the minor comment raised, and have 
included the following statement in the statistical analysis 
section of the manuscript to aid clarity of the methods used:
“This is similar to meta-regression techniques, which assess the 
effect of covariates on the study level estimates.”
As an additional note, it was apparent to the authors that 
statistics about the number of cohorts and studies included in the 
review were those used in an earlier version of the manuscript. 
We apologise for this error, but have made very minor corrections 
to the Abstract, Figure 1 and the second paragraph of the Results 
section describing the number of studies included. Rest assured, 
this had no effect on the results or conclusions of the paper.
Introduction
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes inflammation and 
pain in joints. It is estimated to affect approximately 1% of the UK adult population1. 
Inadequately treated, it can lead to long-term physical damage, namely in the form of bone 
erosions and joint space narrowing, as well as reduced quality of life. The adoption of 
biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in the most severe cases2, as 
well as the introduction of the Treat-2-Target (T2T) approach to disease management in the 
early 2000’s3, which employs the use of early, more aggressive conventional DMARD 
(csDMARD) therapies4 have had a large impact on reducing inflammation and radiographic 
joint damage in recent years5–7. Despite this, there is little indication that this has translated 
into equivalently large, clinically-meaningful improvements in pain, fatigue and health 
related quality of life (HRQoL)8–11. This is of particular importance in RA populations, as 
there is evidence that patients with RA have higher prevalence of psychological distress, 
such as depression and anxiety12–15 compared to the general population and that those 
patients with persistent depression have been evidenced to respond less well to bDMARD 
therapies16. Also, patients with RA with worse quality of life outcomes are associated with 
higher Health Care Resource Utilisation (HCRU)17.
There is a sparsity of systematic reviews, including meta-analysis of quantitative data, 
investigating HRQoL outcomes. Matcham et al.14 is one of the few published systematic 
reviews to investigate HRQoL in observational trials of RA populations, and demonstrated 
that HRQoL was lower in patients with RA when compared to other chronic conditions, such 
as Type 2 diabetes and congestive heart failure. However, much of the data presented were 
cross-sectional in nature, and as such does not document how HRQoL progresses over time, 
or indeed how modern approaches to treatment and management may have impacted on 
disease progression over different periods. To our knowledge, only one other review 
explored HRQoL in older patients with RA (≥75 years) and found that pain, increased age 
and increased functional disability all contributed to worse HRQoL18.
The aim of this systematic review was to examine symptom severity and HRQoL at different 
points during the RA disease course and assess whether there have been changes in 
symptom levels and HRQoL over the last 30 years, in light of the substantial changes in 
treatment strategies over the last few decades. 
Methods
Identifying publications
A systematic search of 3 databases, namely PubMed, EMBASE and PsycInfo, was conducted 
between 1975-2017. The search strategy used key words and MeSH terms on the 
title/abstract and full text as appropriate (See supplementary material for search terms 
used). Additional lateral search techniques included checking reference lists, performing key 
word searches in Google Scholar and using the ‘cited by’ option in PubMed. The review 
included all studies of adult patients (>18 years old) with early RA, where baseline 
assessment was <3 years from symptom onset. Diagnosis was confirmed by either the 1987 
or 2010 American College of Rheumatology (ACR) criteria. As a systematic review of non-
randomised observational cohorts, there was no intervention or comparator group of 
interest in this review.
Outcome(s)
The outcomes of interest were pain, fatigue and mental wellbeing. Pain and fatigue are 
typically measured using a Visual Analogue Scale (VAS), however other measures were 
eligible to be included. Mental health included any measures of quality of life, such as the 
EuroQol 5-Dimensions (EQ-5D) or the Short-Form 36 (SF-36). Other measures relating to 
depression and anxiety were also recorded if reported (e.g. Hospital Anxiety and Depression 
Scores (HADS) and the Beck Depression Inventory (BDI)).
Secondary outcome measures included clinical measures of disease, namely the Disease 
Activity Score (DAS) and measures of functional disability, namely the Health Assessment 
Questionnaire (HAQ).
Inclusion/exclusion criteria
Inclusion criteria to select publications comprised of: (1) included a measure of self-reported 
pain, fatigue or mental well-being, (2) patients had a diagnosis of rheumatoid arthritis, (3) 
baseline assessments occurred no later than 3-years from symptom onset, (4) prospective 
cohort study design, (5) had repeated measures (at least two time points), (6) included 
human participants, and (7) publications written in English.
Publication screening
One reviewer (RB) screened titles/abstracts identified in searches, using the selection 
criteria to identify potentially relevant papers. A second reviewer (LC) independently 
screened the title/abstract of 25% of all publications identified against agreed inclusion 
criteria. Agreement at the title/abstract stage was achieved in 92% of papers, with 
disagreements resolved through discussion (e.g. longitudinal data was only available for a 
subset of patients with established disease, not early disease). Both reviewers (LC & RB) 
then screened all full texts to establish the final set of studies to include in the review. Of 
the 1,736 full texts screened, agreement was achieved for 99.7% of papers.
Data extraction
Three reviewers (LC, RB and PM) extracted data using a pre-designed form, piloted to 
ensure all data necessary were captured. It included: cohort name, country of study 
population, pain/fatigue/mental well-being mean scores and Standard Deviation (SD), along 
with the outcome measure(s) used, number of patients included, years of recruitment, 
length of follow-up, proportion of females in the cohort, mean age of patients in the cohort, 
functional disability mean scores and SD at each recorded follow-up, Disease Activity Score 
mean and SD at each recorded follow-up (where this was recorded using the DAS44 
method, a conversion formula was applied to convert it to DAS2819), proportion of patients 
in the cohort on DMARDS at baseline, proportion of patients in the cohort who were 
Rheumatoid Factor (RF) positive at baseline and number of patients at each follow-up. In 
cases where the raw data were not given in the published paper the author(s) were 
individually contacted to provide this data (n=39).
Quality Assessment
Studies were rated using the Downs and Blacks instrument for non-randomised studies of 
health care interventions20. Since the studies did not examine clinical effectiveness, checklist 
items related to comparative groups (e.g. randomisation and blinding procedures) were 
omitted. One reviewer (LC) scored all studies using the amended checklist and another 
reviewer (PM) independently scored 50% of studies drawn at random. Discrepancies 
between reviewers were discussed and consensus achieved.
Statistical Analysis
The systematic review extracted data at baseline, and all recorded follow-ups, for a range of 
different outcomes measuring disease activity, functional disability, pain, fatigue and mental 
well-being. Whilst traditional meta-analytical methods are used for cross-sectional data, a 
weighted mixed-effects model was needed to account for the aggregate level summary data 
of each time point over time. To account for the longitudinal data structure, Mmultivariate 
meta-analyses were conducted using mixed-effects linear regression models, with a random 
intercept estimated to account for repeated observations within studies and a random slope 
for time allowing the rate of progression to vary within studies over time21. Since the data 
are aggregate level for each included cohort at each time point, they were inverse variance 
weighted using the study level standard error at each recorded time point. Much like a 
meta-analysis, this allows studies with greater sample sizes to given greater weight in the 
estimation of the pooled effect estimate. Full Information Maximum Likelihood (FIML) 
allowed for estimation of time-specific means of every cohort in the event that the data are 
missing. This is similar to meta-regression techniques, which assess the effect of covariates 
on the study level estimates. As such, the figures provided represent the estimated pooled 
mean for that outcome at each follow-up time-point.
Since the cohorts included will be prospective inception cohorts of patients with early RA, it 
was expected that the progression of all outcomes will be non-linear over time. Previous 
research has shown how outcomes such as functional disability follow a ‘J-Shaped’ 
trajectory in the first years of disease22, whereby patients initially improve rapidly in the first 
12-months following treatment initiation, but then worsen in the subsequent years as 
disease duration increases. In order to account for this non-linearity, piecewise linear 
splines were used with a change point at 12-months. This allows for two separate slopes to 
be estimated by the model, one from baseline to 12-months, and one from 12-months to 
60-months. In order to quantify the data from the model, the meta-analysis will be based on 
the estimated pooled effect for each outcome at four pre-specified time points; baseline, 
12-months, 36-months and 60-months.
For each cohort, mid-point between the first and last year of recruitment was used to place 
the cohorts in chronological order from earliest to latest. Cohorts were then split according 
to whether the recruitment was pre or post 2002. This has been used in other reviews due 
to its reflection of the move towards more T2T principles, and also reflects the general 
median year in early RA cohorts in previous reviews23. The dichotomised variable was 
entered into the mixed effect model, along with an interaction effect with follow-up time. 
The mean difference between pre and post -2002 cohorts will be used as the main effect 
estimate. These will be estimated at baseline, 12, 36 and 60-months follow-up for the Pain 
Visual Analogue Scale (VAS), Fatigue VAS, SF-36 PCS, SF-36 MCS, the HAQ and the DAS 
outcomes. Scores <0 indicate more favourable scores for the pre-2002 cohorts, whilst scores 
>0 indicate more favourable scores for the post-2002 cohort. This will be expressed as both 
a mean difference, which highlights the change in score relative to the scale in which it was 
measured, as well as a Standardised Mean Difference (SMD), which allows for direct 
comparisons between measures with different scales. All analyse were conducted using 
Stata (ver15) using the ‘mixed’ command for mixed effects analysis.
Results
A total of 7,319 articles were identified from the 3 databases following the removal of 2,363 
duplicates, as shown in Figure 1. Following title and abstract screening, 1,736 full texts were 
screened for eligibility. In total, 41 articles11,22,32–41,24,42–51,25,52–61,26,62,27–31 describing data 
from 46 cohorts where identified, contributing a combined total of 18,046 patients. The 
median year of recruitment for all cohorts ranged from 1983-2014, with a median year of 
2002. Cohorts recruited patients from twenty different countries (Australia41, Austria62, 
Brazil48, Canada24,49,53,58, Denmark28, France29,32,50, Germany42,46, Iceland54, Italy27,31,56, 
Japan35, Latin American57, The Netherlands25,34,36,40,59, Norway33, Scotland47, South Africa51, 
Spain37,61, Sweden11,38,60, UK22,26,39,55, USA30,43,45,52 and Mexico44). The UK had the highest 
number of cohorts at eight (17%), followed by five (11%) from the Netherlands, and four 
(9%) from Canada, Sweden and the US. The characteristics of the cohorts, and the patients 
included in those cohorts are summarised in Table 1.
Table 1 – Summary table of cohort characteristics, and baseline summary statistics of the 
patients included in the cohorts.
However, aAlthough contact was made with the 39 authors for the additional longitudinal 
data that was required for the meta-analysis, only 9 responded, leaving a total of 29 cohorts 
from 25 studies for inclusion in the meta-analysis. These cohorts contributed a total of 
10,132 patients to the final analyses. With respect to the data collected, 3625 (7886%) had 
longitudinal measures of pain11,22,33,35,37–40,42,44–46,24,47,49–52,54,56–59,26,61,62,27–32, eight813 (28%) 
had measures of fatigue26–28,39,44,46,50,52,56, nine9 (3120%) had measures of SF-
3626,50,51,55,56,59,60, and 2437 (8380%) had measures of the HAQ11,22,34–41,43,44,24,45,47–
52,55,56,59,25,61,62,26,28–30,32,33 and 3725 (806%) had measures of DAS11,22,33–40,42,44,24,45–
47,49,50,52,53,55,56,59,26,61,62,27–32. Alongside SF-36, other longitudinal measures of mental health 
were also collected, namely the Centre for Epidemiological Studies Depression Scale (CES-
D)49,53,58, The Arthritis Impact Measurement Scale (AIMS)26 and the Hospital Anxiety and 
Depression Scale (HADS)47,63, however the small numbers meant it was not possible to 
include them in the meta-analysis.
Figure 1 – Prisma Flow Diagram of journal screening process at each stage of the 
systematic review
Quality Assessment
A modified version of the Down’s and Black Checklist was used to assess the quality of each 
study. Agreement between the two reviewers was high at 99%, and where there were 
differences, these were resolved through consultation.
Overall, all studies included in the meta-analysis were of high quality, with all studies clearly 
defining the hypothesis, characteristics of the patients, main findings, and estimates of 
variability (See supplementary material). The patients included were representative of the 
general population and there were no indications of ‘data dredging’. However, less than 
15% of the studies provided characteristics of their patients who were lost to follow-up, and 
only 20% of the studies appropriately accounted for this loss of follow-up in their analysis.
Whilst >80% of studies were suitably powered, described the principle confounders and 
appropriately accounted for the longitudinal nature of the study in their analysis, <50% of 
studies were found to have used appropriate statistical methods and adequately adjusted 
for all important confounding effects. This was largely due to the reliance on step-wise 
regression methods, which allow for variable selection but introduce bias in parameter 
estimates without regularisation64.
Meta-Analysis
Mean Differences (MD)
The forest plots presented in Figure 2 represent the pooled (model estimated) Mean 
Differences (MD) between pre and post-2002 cohorts at baseline, 12, 36 and 60-months. 
For illustration, the sub-group pooled effect estimate for cohorts recruiting patients post-
2002 for baseline Pain VAS was 52.48 (95% Confidence Intervals 48.92 to 56.05), whereas 
the sub-group pooled effect estimate for cohorts recruiting patients post-2002 was 48.32 
(95% CI 44.51 to 52.13) (Please see Supplementary Material). This , which equates to a MD 
of -4.16 (95% CI -9.34 to 1.01), as shown in Figure 2 (allowing for rounding error).
In order to conceptualise the magnitude of the effects, the reported mean differences for 
each outcome were compared to changes that are deemed clinically important, often 
referred to as the Minimally Clinically Important Difference (MCID). Whilst thresholds vary, 
the MCID for pain VAS has been reported to be 11.965, whilst estimates for the fatigue VAS 
have ranged from 8.2 to 11.2 in RA populations66. Likewise, the MCID has been reported 
between 2.5 to 5.0 for the SF-36 PCS and MCS, however studies have demonstrated higher 
estimates of 7.1 for the SF-36 PCS67. As such, an estimate of 8-unit change has been 
illustrated in Figure 1 for the MCID for the pain, fatigue and SF-36 PCS and MCS. Likewise, a 
MCID of 0.20 was used for HAQ65, and 1.00 for the DAS-2868.
Investigation of the mean differences of all the outcomes between pre- and post-2002 
studies indicate that, at baseline, pre-2002 cohorts had marginally lower levels of pain (-
4.17; 95% CI -9.34 to 1.01), SF-36 MCS (-5.25; 95% CI -11.74 to 1.23) and HAQ (-0.11; 95% CI 
-0.27 to 0.06), whilst pre-2002 cohorts had higher levels of fatigue (3.43; 95% CI -1.32 to 
8.17), SF-36 PCS (0.70; 95% CI -4.23 to 5.62) and DAS (0.18; 95% CI -0.16 to 0.51) at baseline. 
However, none of these differences reached statistical significance (See Figure 21).
By the 12-months, all outcomes exhibit an improvement in scores. However, there is 
variation in the magnitude of this improvement in pre- and post-2002 cohorts for each 
outcome. With the SF-36 PCS there is a statistically significantly greater improvement for 
post-2002 cohorts relative to pre-2002 cohorts, with a MD of 7.66 (95% CI 2.57 to 12.76, 
P<0.05), and likewise for the DAS-28 and fatigue, there was a statistically significantly 
greater improvement for post-2002 cohorts relative to pre-2002 cohorts, with a MD of 0.51 
(95% CI 0.04 to 0.98, P<0.05) and 10.91 (95% CI 5.04 to 16.79) respectively. In contrast, 
whilst pain, SF-36 MCS and HAQ exhibit improvements by 12-months, the magnitude of 
these improvements were much smaller and did not reach statistical significance, with a MD 
of 3.30 (95% CI -2.67 to 9.28), 0.10 (95% CI -4.03 to 4.23) and 0.05 (95% CI -0.15 to 0.25) 
respectively. 
Whilst pain, SF-36 MCS and the HAQ saw incremental improvements in the estimated mean 
differences by the and 36-month and 60-month time points, the estimated mean 
differencesthese improvements were small and did not lead to any statistical differences by 
month 60. indicated a lower score for the post-2002 cohorts for all outcomes measured, 
however only fatigue, SF-36 PCS and DAS indicated a statistically significant difference 
(P<0.05). By month 60, the SF-36 PCS indicated a statistically significantly lower score for 
post-2002 (P=0.003). In contrast, pain, fatigue, SF-36 MCS and HAQ all indicated statistically 
non-significant declines for post-2002 (P>0.1).The SF-36 PCS remained stable over the 36 
and 60-month period, with a statistically significant MD of 7.77 (95% CI 2.68 to 12.87) at 
month 60, whilst the post-2002 cohort continued to see greater improvements over time, 
with statistically significantly greater improvements by month 60 of 0.92 (95% CI 0.38 to 
1.45). Only fatigue saw decreases in improvements over the 36 and 60-month period for the 
post-2002 cohorts, with a statistically non-significant MD of 5.74 (95% CI -1.70 to 13.18) by 
month 60.
Figure 2 – Forest plot of the estimated Mean Difference (MD) for the pain, fatigue, SF-36, 
HAQ and DAS28 outcomes at baseline, 12, 36 and 60-month time-points. Pain, fatigue, SF-
36 PCS and MCS are scored out of 100, whilst the HAQ is scored from 0 to 3 and the DAS28 
from 0 to 8. Points that fall to the left of the zero-line indicate better outcomes in the pre-
2002 cohorts, whilst those that fall to the right of the zero-line indicate better outcomes 
for the post-2002 cohorts. 95% Confidence Intervals are indicated by the horizontal bars 
on the graph and in the brackets of the text. SF-36 PCS = Short-Form 36 Physical 
Component Score, PCS = Short-Form 36 Mental Component Score, HAQ = Health 
Assessment Questionnaire, DAS28 = Disease Activity Score-28
This time dependent trend for pain, fatigue, SF-36, HAQ and DAS28 for both pre-2002 and 
post-2002 cohorts are given in Figure 3. It demonstrates the increased initial response in the 
first 12 months for pain, HAQ and DAS28 for both the pre and post-2002 cohorts, however 
the decrease in pain and HAQ is not as great as the decline in DAS28. In contrast, whilst the 
post-2002 cohorts saw improvements in fatigue, SF-36 PCS and SF-36 MCS in the first 12-
months, the pre-2002 cohorts indicated a more stable progression over the full 60-months. 
By month 60, only the SF-36 PCS and DAS28 scores indicated a significant difference 
between the pre and post-2002 cohorts, with post-2002 cohorts indicating more favourable 
outcomes (P<0.05). However, there was no statistically significant difference between pre 
and post-2002 cohorts over the full 60-months for pain, SF-36 MCS and HAQ. 
Sensitivity analysis
Dichotomising recruitment year into pre- and post-2002 allowed for data to be pooled into 
larger groups, as further stratification would have led to issues with data sparsity of 
outcomes over the follow-up period. However, to ensure that these groups reflected a 
broader linear association with recruitment year, a sensitivity analysis was conducted 
looking at recruitment year as a continuous outcome, rather than a binary outcome. The 
analysis indicated a linear association with recruitment year, with each outcome. In 
corroboration with the main analysis, the main of effect of recruitment year was statistically 
significantly associated with DAS-28, and whilst the other outcomes indicated reductions as 
recruitment year increased, these were smaller effects and did not reach statistical 
significance. A detailed report of this analysis is provided in supplementary material.
Additional analysis investigated the progression of the sub-components of the DAS28; the 
Swollen Joint Count (SJC), Tender Joint Count (TJC), C-Reactive Protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR), in a sub-group of cohorts reporting this data. Of the 
37 cohorts with DAS28 data, 25 had data on SJC, 23 on TJC, 22 on CRP and 18 on ESR. Whilst 
SJCs, TJCs and CRP showed greater declines in post-2002 compared to pre-2002 cohorts, the 
estimates over the follow-up periods were inconclusive due to low levels of data over the 
follow-up. Details of this sub-analysis are presented in the supplementary material.
Figure 3 –Estimated marginal means for the pain, fatigue, SF-36, HAQ and DAS28 
outcomes at baseline, 12, 36 and 60-month time-points. Pain, fatigue, SF-36 PCS and MCS 
are scored out of 100, whilst the HAQ is scored from 0 to 3 and the DAS28 from 0 to 8. 
Circle points with solid black lines indicate the estimated means for the pre-2002 cohorts, 
whilst triangle points with a dashed black line indicate the estimated means for the post-
2002 cohorts. 95% Confidence Intervals are indicated by the grey shaded areas. SF-36 PCS 
= Short-Form 36 Physical Component Score, PCS = Short-Form 36 Mental Component Score, 
HAQ = Health Assessment Questionnaire, DAS28 = Disease Activity Score-28
Standardised Mean Differences (SMD)
Whilst the MD allows for differences to be examined relative to the scale in which the 
outcome was measured, to directly compare the magnitude of the effects of each outcome 
relative to each other, the MD needs to be standardised. The Standardised Mean 
Differences (SMD) for the DAS28 at month-60 comparing post-2002 to pre-2002 cohorts 
was 0.86 (95% CI 0.34 to 1.37), whilst for the SF-36 PCS it was 0.76 (95% CI 0.25 to 1.27), 
indicating that both demonstrated large, statistically significantly lower score for post-2002 
cohorts (P<0.001).
In contrast, the SMD at month-60 comparing post-2002 to pre-2002 cohorts for pain (0.24 
(95% CI -0.25 to 0.74)), fatigue (0.38 (95% CI -0.11-to 0.88)) and HAQ scores (0.34 (95% CI -
0.15-to 0.84)) all indicated small to moderate effect sizes and failed to reach statistical 
significance in favour of post-2002 cohorts. Only the SF-36 MCS indicated improvements in 
favour of pre-2002 cohorts, however the effect was very small and statistically non-
significant (-0.08 (95% CI -0.58 to 0.41)).
Discussion
This review is one of the first to examine the longitudinal trends of important, and well 
reported patient reported outcomes in inflammatory arthritis using meta-analysis. Using 
data from 4629 early RA cohorts, with a combined total of 10,13218,046 patients, the 
longitudinal meta-analysis indicated that whilst patients in more recent cohorts have large, 
statistically significant improvements in levels of disease activity and physical well-being 
over the first 60-months, pain, fatigue, physical functioning and mental well-being indicate 
only small, statistically non-significant improvements.
The reduction in disease activity levels is in general agreement with a previous meta-
analyses that looked at longitudinal rates of structural joint damage, and found that post-
2002 cohorts had statistically significantly lower joint damage than those patients recruited 
pre-200223. Given that both reviews rely on observational cohort data, the exact cause of 
the decline in disease activity, and indeed other objective measures of inflammation, cannot 
be determined directly. However, it is likely that the move towards T2T principles of earlier, 
more aggressive therapies to achieve low/remission based DAS scores, along with the 
increased use of bDMARD therapies, are the main drivers for these secular declines11,23,69. 
Despite large effects in the reduction of disease activity, these do not translate into similar 
improvements in patient reported pain, functional disability and mental well-being. These 
findings are similar to previous meta-analyses investigating data from randomised 
controlled trials (RCT) for both HAQ70, and SF-3671 outcomes. They found that patients 
treated with more aggressive therapies (e.g. combination, or bDMARDs) indicated improved 
function and well-being, however these were not statistically significant, nor did it reflect 
clinically meaningful changes. These findings add more weight to the hypothesis that 
psychological well-being, along with functional disability, may be mediated by factors not 
directly influenced by inflammatory processes10,72.
The precise role of pro-inflammatory cytokines and their association with pain and mental 
health is currently unclear73. Animal model studies have provided evidence of a link 
between Interleukin-1 (IL-1)74,75, IL-676 and TNF-alpha77 on depressive behaviours in mice, 
and cross-sectional cohort studies have shown evidence of elevated pro-inflammatory 
cytokines in patients with depressive symptoms78. However, observational studies fail to 
identify significant associations (both statistically and clinically) between mental health 
symptoms and changes in proteomic markers, such as ESR76. Indeed, this study also found a 
disconnect between fatigue and disease activity over time, suggesting that non-
inflammatory processes may be involved in fatigue symptoms, such as increased levels of 
pain79. As such it is hypothesised that increased inflammation is, in part, explaining elevated 
symptoms in mental well-being and disability, however non-inflammatory processes also 
need to be considered. 
Emerging research is beginning to investigate the relationship between pain and mental 
health could be governed by the mesolimbic dopaminergic reward system80. Reduced levels 
of dopamine have been found in patients with fibromyalgia81,82 and there is evidence that 
activity in the mesolimbic reward system, specifically the role of increased dopamine 
neurotransmission, are strongly linked to positive emotions83,84. Whilst the experience of 
pain itself may be contributing to the reduction of dopaminergic regulation, as evidence by 
reductions in patients with fibromyalgia and chronic back pain85, the role of inflammatory 
makers on this system may also explain the decreased levels in RA specifically86. 
The extent to which inflammation can explain interindividual variability in mental health 
outcomes in all patients, or whether sub-groups of patients exist whereby inflammation 
plays either a lesser or more dominant role in pain experience and mental wellbeing is not 
yet clear. Distinct sub-groups of patients that progress differently over time has been 
evidenced in both functional disability22 and disease activity measures87, which have been 
demonstrated even amongst early RA patients under T2T regimes. Research by Altawil et al. 
has demonstrated how pain remains at high levels in a sub-group of patients, despite 
achieving EULAR remission, suggesting that other mechanisms of pain beyond inflammation 
are responsible88. Understanding factors associated with these different RA sub-groups, and 
how pain, functional disability and well-being progress over the course of the disease, would 
be instrumental in tailoring treatment, both pharmacological and non-pharmacological, at 
the early stages.
The major strengths of the study lie in its large data. The meta-analysis presented in this 
paper is the first, to our best knowledge, to aggregate data on numerous early RA cohorts 
on key clinical and patient reported outcome measures over time, with very large numbers 
of patients. The statistical methods used are novel in the field and allow an accurate 
estimation of each outcome over time, and across different periods. However, the study is 
not without its limitations. Large heterogeneity between studies due to the observational 
nature of the cohort studies included, as well as the breadth of different countries involved, 
makes drawing definitive conclusions on the pooled effect estimates challenging. The 
review includes a broad range of countries representing different GDP per capita, which has 
been shown in previous research to be correlated with disease activity89. There is some 
evidence to suggest socio-economic status plays an important role in the progression of 
functional disability and reduced quality of life90. However, socio-economic status is rarely 
reported in cohorts, making it difficult to analyse its impact in a meta-analytical setting. 
Additionally, eEvery effort was made to minimise the potential bias by restricting cohorts to 
only early RA, as well as adopting a random-effects meta-analysis that assumes there are a 
range of different effects being estimated that follow an approximately normal distribution. 
It is reasonable to assume that country level differences in treatment prescription exist, 
however it is likely that most countries will have followed a similar protocol of T2T, 
employing broadly similar step-up treatment decisions to achieve remission/low disease. 
Data sparsity between the cohort periods over the follow-up for outcomes, such as fatigue, 
are likely to explain some of the statistically non-significant findings. Larger data samples at 
the later follow-up times would help narrow the intervals and provide more precision 
around the true effect. Publication Publication bbias is possible, but unlikely since cohort 
data was sought based on identification through publications that were not dependent on 
positive findings.
In conclusion, this longitudinal meta-analysis provides large scale data highlighting that the 
introduction of more aggressive, T2T based therapies coincided with marked improvements 
in disease activity and physical function over the last few decades during the first 60-months 
of the disease. However, these large-scale improvements in disease activity did not 
translate into equally large improvements in patient reported outcomes, namely pain, 
functional disability and mental well-being. Whilst inflammation remains a key target, 
tThese findings provide clear support for rheumatologists to go beyond the consideration of 
just the DAS in their T2T approach. Non-pharmacological treatments, for managing pain, 
improving functional disability and improving psychological well-being are available and 
need to be more widely adopted in routine care.
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Abstract
Objectives: To conduct a systematic review and longitudinal meta-analysis of early 
rheumatoid arthritis (RA) cohorts with long-term data on pain, fatigue or mental well-being.
Methods: Searches using PUBMED, EMBASE and PyscInfo were performed to identify all 
early RA cohorts with longitudinal measures of pain, fatigue or mental well-being, along 
with clinical measures. Using longitudinal meta-analyses, the progression of each outcome 
over the first 60-months was estimated. Cohorts were stratified based on the median 
recruitment year to investigate secular trends in disease progression.
Results: Of 7,319 papers identified, 75 met the inclusion criteria and 4629 cohorts from 25 
41 publications provided sufficient data on 180,046132 patients for meta-analysis. The 
Disease Activity Scores (DAS28) and the Short-Form 36 (SF-36) Physical Component Score 
(PCS) indicated that post-2002 cohorts had statistically significant improvements over the 
first 60-months compared to pre-2002 cohorts, with standardised mean differences (SMD) 
of 0.86 (95% Confidence Intervals 0.34 to 1.37) and 0.76 (95% CI 0.25 to 1.27) respectively 
at month-60. However, post-2002 cohorts indicated statistically non-significant 
improvements in pain, fatigue, functional disability and SF-36 Mental Component Score 
(MCS) compared to preost-2002 cohorts, with SMD of 0.24 (95% CI -0.25 to 0.74), 0.38 (95% 
CI -0.11 to 0.88), 0.34 (95% CI -0.15-0.84) and -0.08 (95% CI -0.41 to 0.58) at month-60 
respectively.
Conclusions: Recent cohorts indicate improved levels of disease activity and physical quality 
of life, however this has not translated into similar improvements in levels of pain, fatigue 
and functional disability by 60-months.
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Introduction
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes inflammation and 
pain in joints. It is estimated to affect approximately 1% of the UK adult population1. 
Inadequately treated, it can lead to long-term physical damage, namely in the form of bone 
erosions and joint space narrowing, as well as reduced quality of life. The adoption of 
biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in the most severe cases2, as 
well as the introduction of the Treat-2-Target (T2T) approach to disease management in the 
early 2000’s3, which employs the use of early, more aggressive conventional DMARD 
(csDMARD) therapies4 have had a large impact on reducing inflammation and radiographic 
joint damage in recent years5–7. Despite this, there is little indication that this has translated 
into equivalently large, clinically-meaningful improvements in pain, fatigue and health 
related quality of life (HRQoL)8–11. This is of particular importance in RA populations, as 
there is evidence that patients with RA have higher prevalence of psychological distress, 
such as depression and anxiety12–15 compared to the general population and that those 
patients with persistent depression have been evidenced to respond less well to bDMARD 
therapies16. Also, patients with RA with worse quality of life outcomes are associated with 
higher Health Care Resource Utilisation (HCRU)17.
There is a sparsity of systematic reviews, including meta-analysis of quantitative data, 
investigating HRQoL outcomes. Matcham et al.14 is one of the few published systematic 
reviews to investigate HRQoL in observational trials of RA populations, and demonstrated 
that HRQoL was lower in patients with RA when compared to other chronic conditions, such 
as Type 2 diabetes and congestive heart failure. However, much of the data presented were 
cross-sectional in nature, and as such does not document how HRQoL progresses over time, 
or indeed how modern approaches to treatment and management may have impacted on 
disease progression over different periods. To our knowledge, only one other review 
explored HRQoL in older patients with RA (≥75 years) and found that pain, increased age 
and increased functional disability all contributed to worse HRQoL18.
The aim of this systematic review was to examine symptom severity and HRQoL at different 
points during the RA disease course and assess whether there have been changes in 
symptom levels and HRQoL over the last 30 years, in light of the substantial changes in 
treatment strategies over the last few decades. 
Methods
Identifying publications
A systematic search of 3 databases, namely PubMed, EMBASE and PsycInfo, was conducted 
between 1975-2017. The search strategy used key words and MeSH terms on the 
title/abstract and full text as appropriate (See supplementary material for search terms 
used). Additional lateral search techniques included checking reference lists, performing key 
word searches in Google Scholar and using the ‘cited by’ option in PubMed. The review 
included all studies of adult patients (>18 years old) with early RA, where baseline 
assessment was <3 years from symptom onset. Diagnosis was confirmed by either the 1987 
or 2010 American College of Rheumatology (ACR) criteria. As a systematic review of non-
randomised observational cohorts, there was no intervention or comparator group of 
interest in this review.
Outcome(s)
The outcomes of interest were pain, fatigue and mental wellbeing. Pain and fatigue are 
typically measured using a Visual Analogue Scale (VAS), however other measures were 
eligible to be included. Mental health included any measures of quality of life, such as the 
EuroQol 5-Dimensions (EQ-5D) or the Short-Form 36 (SF-36). Other measures relating to 
depression and anxiety were also recorded if reported (e.g. Hospital Anxiety and Depression 
Scores (HADS) and the Beck Depression Inventory (BDI)).
Secondary outcome measures included clinical measures of disease, namely the Disease 
Activity Score (DAS) and measures of functional disability, namely the Health Assessment 
Questionnaire (HAQ).
Inclusion/exclusion criteria
Inclusion criteria to select publications comprised of: (1) included a measure of self-reported 
pain, fatigue or mental well-being, (2) patients had a diagnosis of rheumatoid arthritis, (3) 
baseline assessments occurred no later than 3-years from symptom onset, (4) prospective 
cohort study design, (5) had repeated measures (at least two time points), (6) included 
human participants, and (7) publications written in English.
Publication screening
One reviewer (RB) screened titles/abstracts identified in searches, using the selection 
criteria to identify potentially relevant papers. A second reviewer (LC) independently 
screened the title/abstract of 25% of all publications identified against agreed inclusion 
criteria. Agreement at the title/abstract stage was achieved in 92% of papers, with 
disagreements resolved through discussion (e.g. longitudinal data was only available for a 
subset of patients with established disease, not early disease). Both reviewers (LC & RB) 
then screened all full texts to establish the final set of studies to include in the review. Of 
the 1,736 full texts screened, agreement was achieved for 99.7% of papers.
Data extraction
Three reviewers (LC, RB and PM) extracted data using a pre-designed form, piloted to 
ensure all data necessary were captured. It included: cohort name, country of study 
population, pain/fatigue/mental well-being mean scores and Standard Deviation (SD), along 
with the outcome measure(s) used, number of patients included, years of recruitment, 
length of follow-up, proportion of females in the cohort, mean age of patients in the cohort, 
functional disability mean scores and SD at each recorded follow-up, Disease Activity Score 
mean and SD at each recorded follow-up (where this was recorded using the DAS44 
method, a conversion formula was applied to convert it to DAS2819), proportion of patients 
in the cohort on DMARDS at baseline, proportion of patients in the cohort who were 
Rheumatoid Factor (RF) positive at baseline and number of patients at each follow-up. In 
cases where the raw data were not given in the published paper the author(s) were 
individually contacted to provide this data (n=39).
Quality Assessment
Studies were rated using the Downs and Blacks instrument for non-randomised studies of 
health care interventions20. Since the studies did not examine clinical effectiveness, checklist 
items related to comparative groups (e.g. randomisation and blinding procedures) were 
omitted. One reviewer (LC) scored all studies using the amended checklist and another 
reviewer (PM) independently scored 50% of studies drawn at random. Discrepancies 
between reviewers were discussed and consensus achieved.
Statistical Analysis
The systematic review extracted data at baseline, and all recorded follow-ups, for a range of 
different outcomes measuring disease activity, functional disability, pain, fatigue and mental 
well-being. Whilst traditional meta-analytical methods are used for cross-sectional data, a 
weighted mixed-effects model was needed to account for the aggregate level summary data 
of each time point over time. Multivariate meta-analyses were conducted using mixed-
effects linear regression models, with a random intercept estimated to account for repeated 
observations within studies and a random slope for time allowing the rate of progression to 
vary within studies over time21. Since the data are aggregate level for each included cohort 
at each time point, they were inverse variance weighted using the study level standard error 
at each recorded time point. Much like a meta-analysis, this allows studies with greater 
sample sizes to given greater weight in the estimation of the pooled effect estimate. Full 
Information Maximum Likelihood (FIML) allowed for estimation of time-specific means of 
every cohort in the event that the data are missing. This is similar to meta-regression 
techniques, which assess the effect of covariates on the study level estimates. As such, the 
figures provided represent the estimated pooled mean for that outcome at each follow-up 
time-point.
Since the cohorts included will be prospective inception cohorts of patients with early RA, it 
was expected that the progression of all outcomes will be non-linear over time. Previous 
research has shown how outcomes such as functional disability follow a ‘J-Shaped’ 
trajectory in the first years of disease22, whereby patients initially improve rapidly in the first 
12-months following treatment initiation, but then worsen in the subsequent years as 
disease duration increases. In order to account for this non-linearity, piecewise linear 
splines were used with a change point at 12-months. This allows for two separate slopes to 
be estimated by the model, one from baseline to 12-months, and one from 12-months to 
60-months. In order to quantify the data from the model, the meta-analysis will be based on 
the estimated pooled effect for each outcome at four pre-specified time points; baseline, 
12-months, 36-months and 60-months.
For each cohort, mid-point between the first and last year of recruitment was used to place 
the cohorts in chronological order from earliest to latest. Cohorts were then split according 
to whether the recruitment was pre or post 2002. This has been used in other reviews due 
to its reflection of the move towards more T2T principles, and also reflects the general 
median year in early RA cohorts in previous reviews23. The dichotomised variable was 
entered into the mixed effect model, along with an interaction effect with follow-up time. 
The mean difference between pre and post -2002 cohorts will be used as the main effect 
estimate. These will be estimated at baseline, 12, 36 and 60-months follow-up for the Pain 
Visual Analogue Scale (VAS), Fatigue VAS, SF-36 PCS, SF-36 MCS, the HAQ and the DAS 
outcomes. Scores <0 indicate more favourable scores for the pre-2002 cohorts, whilst scores 
>0 indicate more favourable scores for the post-2002 cohort. This will be expressed as both 
a mean difference, which highlights the change in score relative to the scale in which it was 
measured, as well as a Standardised Mean Difference (SMD), which allows for direct 
comparisons between measures with different scales. All analyse were conducted using 
Stata (ver15) using the ‘mixed’ command for mixed effects analysis.
Results
A total of 7,319 articles were identified from the 3 databases following the removal of 2,363 
duplicates, as shown in Figure 1. Following title and abstract screening, 1,736 full texts were 
screened for eligibility. In total, 41 articles11,22,32–41,24,42–51,25,52–61,26,62,27–31 describing data 
from 46 cohorts where identified, contributing a combined total of 18,046 patients. The 
median year of recruitment for all cohorts ranged from 1983-2014, with a median year of 
2002. Cohorts recruited patients from twenty different countries (Australia41, Austria62, 
Brazil48, Canada24,49,53,58, Denmark28, France29,32,50, Germany42,46, Iceland54, Italy27,31,56, 
Japan35, Latin American57, The Netherlands25,34,36,40,59, Norway33, Scotland47, South Africa51, 
Spain37,61, Sweden11,38,60, UK22,26,39,55, USA30,43,45,52 and Mexico44). The UK had the highest 
number of cohorts at eight (17%), followed by five (11%) from the Netherlands, and four 
(9%) from Canada, Sweden and the US. The characteristics of the cohorts, and the patients 
included in those cohorts are summarised in Table 1.
Table 1 – Summary table of cohort characteristics, and baseline summary statistics of the 
patients included in the cohorts.
Although contact was made with 39 authors for additional longitudinal data, only 9 
responded. With respect to the data collected, 36 (78%) had measures of pain11,22,33,35,37–
40,42,44–46,24,47,49–52,54,56–59,26,61,62,27–32, 13 (28%) had measures of fatigue26–28,39,44,46,50,52,56, nine 
(20%) had measures of SF-3626,50,51,55,56,59,60, 37 (80%) had measures of the HAQ11,22,34–
41,43,44,24,45,47–52,55,56,59,25,61,62,26,28–30,32,33 and 37 (80%) had measures of DAS11,22,33–40,42,44,24,45–
47,49,50,52,53,55,56,59,26,61,62,27–32. Alongside SF-36, other longitudinal measures of mental health 
were also collected, namely the Centre for Epidemiological Studies Depression Scale (CES-
D)49,53,58, The Arthritis Impact Measurement Scale (AIMS)26 and the Hospital Anxiety and 
Depression Scale (HADS)47,63, however the small numbers meant it was not possible to 
include them in the meta-analysis.
Figure 1 – Prisma Flow Diagram of journal screening process at each stage of the 
systematic review
Quality Assessment
A modified version of the Down’s and Black Checklist was used to assess the quality of each 
study. Agreement between the two reviewers was high at 99%, and where there were 
differences, these were resolved through consultation.
Overall, all studies included in the meta-analysis were of high quality, with all studies clearly 
defining the hypothesis, characteristics of the patients, main findings, and estimates of 
variability (See supplementary material). The patients included were representative of the 
general population and there were no indications of ‘data dredging’. However, less than 
15% of the studies provided characteristics of their patients who were lost to follow-up, and 
only 20% of the studies appropriately accounted for this loss of follow-up in their analysis.
Whilst >80% of studies were suitably powered, described the principle confounders and 
appropriately accounted for the longitudinal nature of the study in their analysis, <50% of 
studies were found to have used appropriate statistical methods and adequately adjusted 
for all important confounding effects. This was largely due to the reliance on step-wise 
regression methods, which allow for variable selection but introduce bias in parameter 
estimates without regularisation64.
Meta-Analysis
Mean Differences (MD)
The forest plots presented in Figure 2 represent the pooled (model estimated) Mean 
Differences (MD) between pre and post-2002 cohorts at baseline, 12, 36 and 60-months. 
For illustration, the sub-group pooled effect estimate for cohorts recruiting patients post-
2002 for baseline Pain VAS was 52.48 (95% Confidence Intervals 48.92 to 56.05), whereas 
the sub-group pooled effect estimate for cohorts recruiting patients post-2002 was 48.32 
(95% CI 44.51 to 52.13) (Please see Supplementary Material). This equates to a MD of -4.16 
(95% CI -9.34 to 1.01), as shown in Figure 2 (allowing for rounding error).
In order to conceptualise the magnitude of the effects, the reported mean differences for 
each outcome were compared to changes that are deemed clinically important, often 
referred to as the Minimally Clinically Important Difference (MCID). Whilst thresholds vary, 
the MCID for pain VAS has been reported to be 11.965, whilst estimates for the fatigue VAS 
have ranged from 8.2 to 11.2 in RA populations66. Likewise, the MCID has been reported 
between 2.5 to 5.0 for the SF-36 PCS and MCS, however studies have demonstrated higher 
estimates of 7.1 for the SF-36 PCS67. As such, an estimate of 8-unit change has been 
illustrated in Figure 1 for the MCID for the pain, fatigue and SF-36 PCS and MCS. Likewise, a 
MCID of 0.20 was used for HAQ65, and 1.00 for the DAS-2868.
Investigation of the mean differences of all the outcomes between pre- and post-2002 
studies indicate that, at baseline, pre-2002 cohorts had marginally lower levels of pain (-
4.17; 95% CI -9.34 to 1.01), SF-36 MCS (-5.25; 95% CI -11.74 to 1.23) and HAQ (-0.11; 95% CI 
-0.27 to 0.06), whilst pre-2002 cohorts had higher levels of fatigue (3.43; 95% CI -1.32 to 
8.17), SF-36 PCS (0.70; 95% CI -4.23 to 5.62) and DAS (0.18; 95% CI -0.16 to 0.51) at baseline. 
However, none of these differences reached statistical significance (See Figure 2).
By 12-months, all outcomes exhibit an improvement in scores. However, there is variation in 
the magnitude of this improvement in pre- and post-2002 cohorts for each outcome. With 
the SF-36 PCS there is a statistically significantly greater improvement for post-2002 cohorts 
relative to pre-2002 cohorts, with a MD of 7.66 (95% CI 2.57 to 12.76, P<0.05), and likewise 
for the DAS-28 and fatigue, there was a statistically significantly greater improvement for 
post-2002 cohorts relative to pre-2002 cohorts, with a MD of 0.51 (95% CI 0.04 to 0.98, 
P<0.05) and 10.91 (95% CI 5.04 to 16.79) respectively. In contrast, whilst pain, SF-36 MCS 
and HAQ exhibit improvements by 12-months, the magnitude of these improvements were 
much smaller and did not reach statistical significance, with a MD of 3.30 (95% CI -2.67 to 
9.28), 0.10 (95% CI -4.03 to 4.23) and 0.05 (95% CI -0.15 to 0.25) respectively.
Whilst pain, SF-36 MCS and the HAQ saw incremental improvements in the estimated mean 
differences by the 36-month and 60-month time points, these improvements were small 
and did not lead to any statistical differences by month 60. The SF-36 PCS remained stable 
over the 36 and 60-month period, with a statistically significant MD of 7.77 (95% CI 2.68 to 
12.87) at month 60, whilst the post-2002 cohort continued to see greater improvements 
over time, with statistically significantly greater improvements by month 60 of 0.92 (95% CI 
0.38 to 1.45). Only fatigue saw decreases in improvements over the 36 and 60-month period 
for the post-2002 cohorts, with a statistically non-significant MD of 5.74 (95% CI -1.70 to 
13.18) by month 60.
Figure 2 – Forest plot of the estimated Mean Difference (MD) for the pain, fatigue, SF-36, 
HAQ and DAS28 outcomes at baseline, 12, 36 and 60-month time-points. Pain, fatigue, SF-
36 PCS and MCS are scored out of 100, whilst the HAQ is scored from 0 to 3 and the DAS28 
from 0 to 8. Points that fall to the left of the zero-line indicate better outcomes in the pre-
2002 cohorts, whilst those that fall to the right of the zero-line indicate better outcomes 
for the post-2002 cohorts. 95% Confidence Intervals are indicated by the horizontal bars 
on the graph and in the brackets of the text. SF-36 PCS = Short-Form 36 Physical 
Component Score, PCS = Short-Form 36 Mental Component Score, HAQ = Health 
Assessment Questionnaire, DAS28 = Disease Activity Score-28
This time dependent trend for pain, fatigue, SF-36, HAQ and DAS28 for both pre-2002 and 
post-2002 cohorts are given in Figure 3. It demonstrates the increased initial response in the 
first 12 months for pain, HAQ and DAS28 for both the pre and post-2002 cohorts, however 
the decrease in pain and HAQ is not as great as the decline in DAS28. In contrast, whilst the 
post-2002 cohorts saw improvements in fatigue, SF-36 PCS and SF-36 MCS in the first 12-
months, the pre-2002 cohorts indicated a more stable progression over the full 60-months. 
By month 60, only the SF-36 PCS and DAS28 scores indicated a significant difference 
between the pre and post-2002 cohorts, with post-2002 cohorts indicating more favourable 
outcomes (P<0.05). However, there was no statistically significant difference between pre 
and post-2002 cohorts over the full 60-months for pain, SF-36 MCS and HAQ. 
Sensitivity analysis
Dichotomising recruitment year into pre- and post-2002 allowed for data to be pooled into 
larger groups, as further stratification would have led to issues with data sparsity of 
outcomes over the follow-up period. However, to ensure that these groups reflected a 
broader linear association with recruitment year, a sensitivity analysis was conducted 
looking at recruitment year as a continuous outcome, rather than a binary outcome. The 
analysis indicated a linear association with recruitment year, with each outcome. In 
corroboration with the main analysis, the main of effect of recruitment year was statistically 
significantly associated with DAS-28, and whilst the other outcomes indicated reductions as 
recruitment year increased, these were smaller effects and did not reach statistical 
significance. A detailed report of this analysis is provided in supplementary material.
Additional analysis investigated the progression of the sub-components of the DAS28; the 
Swollen Joint Count (SJC), Tender Joint Count (TJC), C-Reactive Protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR), in a sub-group of cohorts reporting this data. Of the 
37 cohorts with DAS28 data, 25 had data on SJC, 23 on TJC, 22 on CRP and 18 on ESR. Whilst 
SJCs, TJCs and CRP showed greater declines in post-2002 compared to pre-2002 cohorts, the 
estimates over the follow-up periods were inconclusive due to low levels of data over the 
follow-up. Details of this sub-analysis are presented in the supplementary material.
Figure 3 –Estimated marginal means for the pain, fatigue, SF-36, HAQ and DAS28 
outcomes at baseline, 12, 36 and 60-month time-points. Pain, fatigue, SF-36 PCS and MCS 
are scored out of 100, whilst the HAQ is scored from 0 to 3 and the DAS28 from 0 to 8. 
Circle points with solid black lines indicate the estimated means for the pre-2002 cohorts, 
whilst triangle points with a dashed black line indicate the estimated means for the post-
2002 cohorts. 95% Confidence Intervals are indicated by the grey shaded areas. SF-36 PCS 
= Short-Form 36 Physical Component Score, PCS = Short-Form 36 Mental Component Score, 
HAQ = Health Assessment Questionnaire, DAS28 = Disease Activity Score-28
Standardised Mean Differences (SMD)
Whilst the MD allows for differences to be examined relative to the scale in which the 
outcome was measured, to directly compare the magnitude of the effects of each outcome 
relative to each other, the MD needs to be standardised. The Standardised Mean 
Differences (SMD) for the DAS28 at month-60 comparing post-2002 to pre-2002 cohorts 
was 0.86 (95% CI 0.34 to 1.37), whilst for the SF-36 PCS it was 0.76 (95% CI 0.25 to 1.27), 
indicating that both demonstrated large, statistically significantly lower score for post-2002 
cohorts (P<0.001).
In contrast, the SMD at month-60 comparing post-2002 to pre-2002 cohorts for pain (0.24 
(95% CI -0.25 to 0.74)), fatigue (0.38 (95% CI -0.11-to 0.88)) and HAQ scores (0.34 (95% CI -
0.15-to 0.84)) all indicated small to moderate effect sizes and failed to reach statistical 
significance in favour of post-2002 cohorts. Only the SF-36 MCS indicated improvements in 
favour of pre-2002 cohorts, however the effect was very small and statistically non-
significant (-0.08 (95% CI -0.58 to 0.41)).
Discussion
This review is one of the first to examine the longitudinal trends of important, and well 
reported patient reported outcomes in inflammatory arthritis using meta-analysis. Using 
data from 46 early RA cohorts, with a combined total of 18,046 patients, the longitudinal 
meta-analysis indicated that whilst patients in more recent cohorts have large, statistically 
significant improvements in levels of disease activity and physical well-being over the first 
60-months, pain, fatigue, physical functioning and mental well-being indicate only small, 
statistically non-significant improvements.
The reduction in disease activity levels is in general agreement with a previous meta-
analyses that looked at longitudinal rates of structural joint damage, and found that post-
2002 cohorts had statistically significantly lower joint damage than those patients recruited 
pre-200223. Given that both reviews rely on observational cohort data, the exact cause of 
the decline in disease activity, and indeed other objective measures of inflammation, cannot 
be determined directly. However, it is likely that the move towards T2T principles of earlier, 
more aggressive therapies to achieve low/remission based DAS scores, along with the 
increased use of bDMARD therapies, are the main drivers for these secular declines11,23,69. 
Despite large effects in the reduction of disease activity, these do not translate into similar 
improvements in patient reported pain, functional disability and mental well-being. These 
findings are similar to previous meta-analyses investigating data from randomised 
controlled trials (RCT) for both HAQ70, and SF-3671 outcomes. They found that patients 
treated with more aggressive therapies (e.g. combination, or bDMARDs) indicated improved 
function and well-being, however these were not statistically significant, nor did it reflect 
clinically meaningful changes. These findings add more weight to the hypothesis that 
psychological well-being, along with functional disability, may be mediated by factors not 
directly influenced by inflammatory processes10,72.
The precise role of pro-inflammatory cytokines and their association with pain and mental 
health is currently unclear73. Animal model studies have provided evidence of a link 
between Interleukin-1 (IL-1)74,75, IL-676 and TNF-alpha77 on depressive behaviours in mice, 
and cross-sectional cohort studies have shown evidence of elevated pro-inflammatory 
cytokines in patients with depressive symptoms78. However, observational studies fail to 
identify significant associations (both statistically and clinically) between mental health 
symptoms and changes in proteomic markers, such as ESR76. Indeed, this study also found a 
disconnect between fatigue and disease activity over time, suggesting that non-
inflammatory processes may be involved in fatigue symptoms, such as increased levels of 
pain79. As such it is hypothesised that increased inflammation is, in part, explaining elevated 
symptoms in mental well-being and disability, however non-inflammatory processes also 
need to be considered. 
Emerging research is beginning to investigate the relationship between pain and mental 
health could be governed by the mesolimbic dopaminergic reward system80. Reduced levels 
of dopamine have been found in patients with fibromyalgia81,82 and there is evidence that 
activity in the mesolimbic reward system, specifically the role of increased dopamine 
neurotransmission, are strongly linked to positive emotions83,84. Whilst the experience of 
pain itself may be contributing to the reduction of dopaminergic regulation, as evidence by 
reductions in patients with fibromyalgia and chronic back pain85, the role of inflammatory 
makers on this system may also explain the decreased levels in RA specifically86. 
The extent to which inflammation can explain interindividual variability in mental health 
outcomes in all patients, or whether sub-groups of patients exist whereby inflammation 
plays either a lesser or more dominant role in pain experience and mental wellbeing is not 
yet clear. Distinct sub-groups of patients that progress differently over time has been 
evidenced in both functional disability22 and disease activity measures87, which have been 
demonstrated even amongst early RA patients under T2T regimes. Research by Altawil et al. 
has demonstrated how pain remains at high levels in a sub-group of patients, despite 
achieving EULAR remission, suggesting that other mechanisms of pain beyond inflammation 
are responsible88. Understanding factors associated with these different RA sub-groups, and 
how pain, functional disability and well-being progress over the course of the disease, would 
be instrumental in tailoring treatment, both pharmacological and non-pharmacological, at 
the early stages.
The major strengths of the study lie in its large data. The meta-analysis presented in this 
paper is the first, to our best knowledge, to aggregate data on numerous early RA cohorts 
on key clinical and patient reported outcome measures over time, with very large numbers 
of patients. The statistical methods used are novel in the field and allow an accurate 
estimation of each outcome over time, and across different periods. However, the study is 
not without its limitations. Large heterogeneity between studies due to the observational 
nature of the cohort studies included, as well as the breadth of different countries involved, 
makes drawing definitive conclusions on the pooled effect estimates challenging. The 
review includes a broad range of countries representing different GDP per capita, which has 
been shown in previous research to be correlated with disease activity89. There is some 
evidence to suggest socio-economic status plays an important role in the progression of 
functional disability and reduced quality of life90. However, socio-economic status is rarely 
reported in cohorts, making it difficult to analyse its impact in a meta-analytical setting. 
Additionally, every effort was made to minimise the potential bias by restricting cohorts to 
only early RA, as well as adopting a random-effects meta-analysis that assumes there are a 
range of different effects being estimated that follow an approximately normal distribution. 
It is reasonable to assume that country level differences in treatment prescription exist, 
however it is likely that most countries will have followed a similar protocol of T2T, 
employing broadly similar step-up treatment decisions to achieve remission/low disease. 
Data sparsity between the cohort periods over the follow-up for outcomes, such as fatigue, 
are likely to explain some of the statistically non-significant findings. Larger data samples at 
the later follow-up times would help narrow the intervals and provide more precision 
around the true effect. Publication bias is possible, but unlikely since cohort data was 
sought based on identification through publications that were not dependent on positive 
findings.
In conclusion, this longitudinal meta-analysis provides large scale data highlighting that the 
introduction of more aggressive, T2T based therapies coincided with improvements in 
disease activity and physical function over the last few decades during the first 60-months 
of the disease. However, these large-scale improvements in disease activity did not 
translate into equally large improvements in patient reported outcomes, namely pain, 
functional disability and mental well-being. Whilst inflammation remains a key target, these 
findings provide clear support for rheumatologists to go beyond the consideration of just 
the DAS in their T2T approach. Non-pharmacological treatments, for managing pain, 
improving functional disability and improving psychological well-being are available and 
need to be more widely adopted in routine care.
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Year 
Published Cohort Country
Year 
Recruited
Followup 
(Months) N
Baseline Pain 
(Mean (SD))
Baseline Fatigue 
(Mean (SD))
Baseline SF36 
PCS (Mean 
(SD))
Baseline SF36 
MCS (Mean 
(SD))
Baseline HAQ 
(Mean (SD))
Baseline DAS 
(Mean (SD)) Age
Female 
(%)
RF + 
(%)
Ahlstrand et al. 2015 TIRA-1 Sweden 1996 1998 36 276 48.10 (25) 0.90 (0.6) 5.20 (1.2) 56 69
Ahlstrand et al. 2015 TIRA-2 Sweden 2006 2009 36 373 52.60 (24) 1.00 (0.6) 5.10 (1.3) 59 67
Ajeganova et al. 2016 Leiden Netherlands 1993 2011 120 886 1.00 (0.87) 57 67 59
Amjadi et al. 2009
Mexico/US 
cohort USA/Mexico 1993 2009 12 277 58.90 (28) 52.60 (24.3) 1.20 (0.7) 6.00 (1.1) 51 77
Barnabe et al. 2015 CATCH Canada 2007 2014 24 1586 5.50 (2.9) 1.03 (0.71) 5.06 (1.45) 54 73 66
Callhoff et al. 2015 CAPEA cohort Germany 2010 2013 24 512 5.42 (2.6) 3.90 (2.86) 4.40 (1.4) 47 68 57
Cantini et al. 2012 Prato Cohort RA Italy 2008 2010 36 55 69.00 (11) 62.00 (14.9) 5.48 (0.34) 50 40 89
Che et al. 2014 ESPOIR Cohort France 2002 2005 60 664 39.60 (28) 48.90 (27.4) 37.90 (8.4) 39.30 (10.8) 1.03 (0.69) 5.30 (1.2) 49 77 46
Christensen et 
al. 2016
Copenhagen 
Cohort Denmark 2013 2014 4 102 49.94 (24) 56.28 (26.9) 1.05 (0.65) 4.48 (1.1) 55 75 64
Combe et al. 2003 French Cohorts France 1993 1994 60 140 57.50 (22) 1.30 (0.7) 4.10 (0.8) 51 73 81
Craig et al. 2010 CLEAR USA 2000 2010 36 266 6.10 (2.9) 1.59 (0.92) 3.90 (1.5) 51 81 69
Da Mota et al. 2012 Brazil Cohort Brazil 2012 2012 36 40 1.89 (0.78) 45 90
Dale et al. 2016 SERA Scotland 2011 2015 24 1073 51.96 (28) 1.17 (0.79) 4.74 (1.34) 58 65 72
Di Franco et al. 2015 Rome Cohort Italy 2010 2012 12 37 63.00 (24) 5.18 (1) 47 84 83
Dobkin et al. 2013 CHUS Cohort Canada 2006 2011 12 211 48.90 (27) 0.79 (0.61) 4.80 (1.4) 59 63 33
Flipon et al. 2009 VeRA France 1998 2001 0 180 42.90 (26) 1.00 (0.72) 3.22 (1.3) 56 71
Garcia et al. 2009 PROAR Spain 2001 2005 60 171 55.21 (24) 1.40 (0.71) 5.80 (1.19) 54 70 52
Gwinnutt et al. 2017 NOAR-Cohort 1 UK 1990 1994 120 608 1.09 (0.737) 4.69 (1.19) 55 66 52
Gwinnutt et al. 2017 NOAR-Cohort 2 UK 1995 1999 84 453 1.13 (0.761) 4.48 (1.22) 57 69 59
Gwinnutt et al. 2017 NOAR-Cohort 3 UK 2000 2004 120 340 45.38 (26) 49.31 (27.2) 31.71 (9.89) 45.94 (11.9) 1.23 (0.765) 4.25 (1.12) 58 69 69
Gwinnutt et al. 2017 NOAR-Cohort 4 UK 2005 2008 120 304 46.84 (26) 50.78 (28.5) 1.18 (0.702) 4.42 (1.18) 55 69 74
Haugeberg et 
al. 2015 Norway Cohort Norway 1999 2001 120 94 44.20 (25) 0.69 (0.51) 5.20 (1.1) 50 62 68
Hodkinson et al. 2012 GREAT Registry South Africa 2005 2008 12 171 66.10 (25) 34.20 (16.9) 44.90 (18.5) 1.67 (0.79) 47 82 85
Jansen et al. 2000
Amsterdam 
Cohort Netherlands 1995 1996 12 133 1.10 (0.8) 5.40 (1.2) 64 68 50
Jawaheer et al.
2010
West US & 
Mexico Cohort USA 1993 2002 24 292 60.40 (27) 52.00 (24.6) 1.20 (0.7) 5.10 (1.1) 50 75 72
Kaneko et al. 2014 SAKURA Cohort Japan 2007 2009 12 75 43.90 (29) 0.76 (0.713) 4.52 (1.15) 61 86 79
Kievit et al. 2006 UMCN/SMK Netherlands 1985 2004 36 908 0.77 (0.6) 5.20 (1.3) 54 66 77
Leblanc-
Trudeau et al. 2015 EUPA Canada 1998 2013 42 275 4.80 (1.9) 60 63 36
Machold et al. 2007 AEAA Austria 1996 2001 36 55 48.60 (22) 0.91 (0.89) 5.60 (1) 52 76 44
Manfredsdottir 
et al. 2006
Reykjavik 
Cohort Iceland 1997 2000 24 100 6.30 (2.5) 53 57 47
McWilliams et 
al. 2013 ERAN UK 2002 2011 60 997 29.12 (12.1) 47.30 (11.7) 1.08 (0.76) 4.68 (1.56) 57 68 53
Norton et al. 2013 ERAS UK 1986 2001 120 1465 43.97 (26) 1.15 (0.769) 4.77 (1.26) 55 66 73
Paulus et al. 2000
US Western 
Consortium 
Cohort USA 1993 1996 24 180 60.10 (27) 1.22 (0.73) 4.92 (1.14) 52 78
Picchianti-
Diamanti  et al. 2010
Rome RA 
Cohort Italy 2005 2006 24 20 58.50 (24) 77.70 (11.8) 25.60 (3.9) 29.50 (9) 1.16 (0.6) 4.90 (1.1) 53 75
Ramagli et al. 2015
REPANARC 
Cohort Latin America 2010 2013 24 173 6.00 (2.7) 42 84 47
Sanmarti et al. 2003
Barcalona 
Cohort Spain 1998 2000 12 60 51.20 (22) 1.00 (0.5) 5.80 (0.8) 52 78 78
Schieir et al. 2009 McEar Canada 2004 2007 6 320 8.00 (8.6) 57 69
Steunebrink et 
al. 2016 DREAM Registry Netherlands 2012 2015 12 91 58.40 (22) 37.30 (9.2) 44.80 (11.8) 0.90 (0.7) 4.90 (1.2) 59 60 58
Svensson et al. 2016 BARFOT Sweden 1993 1999 96 640 45.00 (24) 1.00 (0.6) 5.10 (1.2) 54 66 60
Twigg et al. 2017 IACON UK 2010 2014 24 384 4.60 (2.8) 4.40 (2.9) 1.12 (0.73) 3.94 (1.4) 56 70 57
Twigg et al. 2017 YEAR UK 2002 2009 24 725 5.80 (2.6) 4.50 (2.6) 1.27 (0.75) 4.70 (1.5) 58 67 70
van der Leeden 
et al. 2010 EAC Netherlands 1995 2007 96 845 50.82 (25) 1.21 (0.76) 5.20 (1.2) 55 69 51
Wechalekar et 
al. 2016
Adelaide EAC 
Cohort Australia 2000 2014 36 263 0.76 (0.55) 55 71 60
West et al. 2009 Umea Cohort Sweden 1996 1998 72 50 33.10 (11.5) 48.40 (10.1) 51 68 92
Westhoff et al. 2008 German Cohort Germany 2000 2001 36 916 4.30 (2.6) 4.79 (1.5) 57 70
Wolfe et al. 1998 Withita Cohort USA 1973 1993 228 256 0.89 (0.7) 52 73 74
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27. Did the study have sufficient power to detect aclinically important
effect where the probability value for a differencebeing due to chance…
26. Were losses ofpatients to follow-up taken into account?
25. Was there adequateadjustment for confounding in the analyses from
which the main findings were drawn?
24. Was the randomised intervention assignment concealed fromboth
patients and health carestaff until recruitment was complete and…
23. Werestudy subjects randomised to intervention groups?
22. Werestudy subjects in different intervention groups (trials and cohort
studies)or were the cases and controls (case-control studies) recruited…
21. Werethe patients in different intervention groups (trials and cohort
studies)or were the cases and controls (case-control studies) recruited…
20. Werethe main outcome measures used accurate (valid and reliable)?
19. Was compliance with the intervention/s reliable?
18. Werethe statistical tests used to assess the main outcomes
appropriate?
17. In trials and cohort studies, do theanalyses adjust for different lengths
of follow-up of patients?
16. If any of the results of the study were based on “data dredging”, was 
this made clear?
15. Was an attempt made to blind those measuring the main outcomes of
the intervention?
14. Was an attempt made to blind study subjects to the intervention they
have received?
13. Werethe staff, places, and facilities where the patients weretreated,
representative of the treatment the majority ofpatients receive?
12. Werethosesubjects who were prepared to participaterepresentative
of the entirepopulation from which they were recruited?
11. Werethe subjects asked to participate in the study representative of
the entire population from which they were recruited?
10. Have actual probability values been reported
9. Have thecharacteristics of patients lost to follow-up been described?
8. Have all important adverse events that may be aconsequence of the
intervention been reported?
7. Does the study provide estimates of therandom variability in the data
for the main outcomes?
6. Are the main findings of the study clearly described?
5. Are the distributions of principal confounders in each group of subjects
to be compared clearly described?
4. Are the interventions of interest clearly described?
3. Are the characteristics of the patients included in the study clearly
described?
2. Are the main outcomes to be measured clearly described in the
Introduction or Methods section?
1. Is the hypothesis/aim/objectiveof thestudy clearly described?
Downs andBlacks QualityAssessment
Yes
No
N/A
Proportion of studies answering yes, no and N/A to the 27 items of the Downs and Blacks quality 
assessment tool. Items 4, 8, 12, 14, 15, 29, 21, 22, 23 & 24 were not completed since they asked 
about trial procedures.
A table to illustrate which items each study were reported as satisfying (green) or not satisfying (red) for 
each of the items of the Downs and Blacks quality assessment tool. Items 4, 8, 12, 14, 15, 29, 21, 
22, 23 & 24 were not completed since they asked about trial procedures.
Sensitivity Analysis looking at recruitment year as a continuous 
outcome
A sensitivity analysis was conducted to investigate whether there was a linear association 
between the studies year of recruitment with the progression of each outcome over the 
follow-up period. Rather than including recruitment year as a binary outcome, it was 
entered in the mixed effects model as a continuous outcome, along with an interaction 
effect with follow-up period.
The model estimated means of each outcome over the 60-month follow-up at 5-year 
intervals for recruitment year (1990, 1995, 2000 and 2005) are presented in the figure 
below. Each line represents the model estimated means for those specific recruitment 
years.
Supplementary Figure 1 - Estimated marginal means for the pain, fatigue, SF-36, HAQ and DAS28 outcomes 
at baseline, 12, 36 and 60-month with year of recruitment expressed as a continuous measure. Pain, fatigue, 
SF-36 PCS and MCS are scored out of 100, whilst the HAQ is scored from 0 to 3 and the DAS28 from 0 to 8. 
Circle points with solid black lines indicate the estimated means for cohorts in 1990, triangle points with a 
dashed black line indicate the estimated means for cohorts in 1995, diamond points with dotted black line 
indicate the estimated means for cohorts in 2000 and square points with solid black line indicated estimated 
means for cohorts in 2005. SF-36 PCS = Short-Form 36 Physical Component Score, PCS = Short-Form 36 
Mental Component Score, HAQ = Health Assessment Questionnaire, DAS28 = Disease Activity Score-28
The models demonstrated a statistically significant main effect of recruitment year for the 
DAS-28, showing a reduction of -0.03 (95% Confidence Intervals -0.05 to -0.01, p<0.05). 
However, the estimated effect of recruitment year was non-significant for HAQ (-0.003, 95% 
CI’s -0.01 to 0.01), SF36 MCS (-0.04, 95% CI’s -0.43 to 0.34), SF-36 PCS (0.25, 95% CI’s -0.07 
to 0.57), fatigue (-0.54, 95% CI’s -1.35 to 0.27) and pain (-0.04, 95% CI’s -0.44 to 0.36).
The linear association corroborates with the main analysis looking at recruitment year as a 
dichotomous outcome.
Sensitivity Analysis looking at the Disease Activity Score-28 (DAS28) 
component scores – Swollen Joint Count-28 (SJC-28), Tender Joint 
Count-28 (TJC-28), C-Reactive Protein (CRP) and Erythrocyte 
Sedimentation Rate (ESR).
Additional sensitivity analysis was conducted to investigate the progression of the sub-
components of the Disease Activity Score-28 (DAS28), which included the Swollen Joint 
Count (SJC), Tender Joint Count (TJC) and acute phase markers: C-Reactive Protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR). Of the 37 cohorts that had reported DAS28, 30 had 
data on the SJC, 27 had data on TJC, 18 had data on ESR and 22 had data on CRP. The 28-
joint count version of the SJC and TJC was the more prominent measure used, with 25 (83%) 
of the 30 cohorts reporting the SJC-28 and 23 (85%) of the 27 cohorts reporting the TJC-28. 
Given the complexities in combining joint counts of different maximum scores, this 
sensitivity analysis focuses only on the SJC-28 and the TJC-28.
Mixed-effects models indicate a statistically significant improvements in SJC-28 at baseline 
for cohorts recruiting patients post-2002 compared to those recruiting patients pre-2002, 
with a Mean Difference (MD) of 2.02 (95% Confidence Intervals (CI) -3.94 to -0.10, P<0.05). 
This improvement remained relatively stable over the course of the follow-up, however the 
decreased precision results in statistically non-significant effects, indicating MD scores in 
favour of post-2002 cohorts at 1.41 (95% CIs -4.19 to 1.38), 1.79 (95% CIs -4.61 to 1.02) and 
2.18 (95% CIs -5.10 to 0.74, P<0.05) at the 12, 36 and 60-month follow-up periods.
Similarly, there was some evidence of a decreased level of TJC-28 between those cohorts 
recruiting patients post-2002 and those recruiting patients pre-2002 at baseline, with a 
statistically significant MD score of -1.78 (95% CIs -3.55 to -0.02), however the MD estimates 
reduced in months 12 (-0.10; 95% CIs -3.29 to 3.10) and 36 (-0.60; 95% CIs -3.59 to 2.39), 
but increased to similar levels at baseline by month 60 (-1.10; 95% CIs -3.98 to 1.78). 
However, imprecision of the point estimates led to large uncertainty and statistical non-
significance of these estimates.
Whereas estimates for ESR demonstrated little difference between the pre- and post-2002 
cohorts, with very small, statistically non-significant MD estimates at baseline (-2.02; 95% 
CIs -11.72 to 7.67), 12 (0.98; 95% CIs -9.47 to 11.42), 36 (0.08; 95% CIs -10.39 to 10.56) and 
60 (-0.81; 95% CIs -11.32 to 9.71), CRP demonstrated a more consistent, albeit statistically 
non-significant, effect from baseline to month 60, with improved CRP scores at the baseline, 
12, 36 and 60-month time points of 4.60 (95% CIs -13.92 to 4.72), 4.60 (95% CIs -11.18 to 
1.97), 4.02 (95% CIs -10.66 to 2.62) and 3.43 (95% CIs -10.22 to 3.35) for the post-2002 
cohorts relative to the pre-2002 cohort. However, low numbers of data points, particularly 
at the later follow-up time-points, led to large imprecision around these estimates.
The estimates for both the SJC-28, TJC-28, ESR and CRP outcomes over the 60-month follow-
up period for both pre and post-2002 cohorts are presented graphically in Supplementary 
Figure 1.
Supplementary Figure 2 - Estimated marginal means for the Swollen Joint Count (SJC), Tender Joint Count 
(TJC), Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) outcomes at baseline, 12, 36 and 
60-month time-points. The Joint counts are scored out of 28. Circle points with solid black lines indicate the 
estimated means for the pre-2002 cohorts, whilst triangle points with a dashed black line indicate the 
estimated means for the post-2002 cohorts. 95% Confidence Intervals are indicated by the grey shaded 
areas.
Forest plots of each outcome at baseline, 1, 3 and 5-year follow-up 
from all cohort studies included in the review











